Xarelto is a new generation anticoagulant or blood thinning drug, which is formulated as a direct thrombin inhibitor (DTI) like Pradaxa, against which it was meant to compete. It is manufactured by the pharmaceutical giants Johnson & Johnson’s Janssen Pharmaceuticals and Bayer Health Care. This blood thinning prescription drug was approved by the US Food and Drug Administration (FDA) in July 2011: to avert any risk of blood clot formation in the lungs, which is a condition called pulmonary embolism; to reduce chances of deep vein thrombosis (DVT), which is blood clotting in the deep veins, usually in the legs, after a knee surgery of total hip replacement surgery; and to prevent chances of stroke and/or blood clot formation in people suffering atrial fibrillation, which is an irregularity in heartbeat.

Many individuals prescribed with Xarelto have reported experiencing one of the following side-effects of the drug shortly after using it: blood in urine; bright red or black feces; vomiting and/or coughing up of blood; frequent nosebleeds; weakness, dizziness, or headaches; swelling and/or at wound sites; brain hemorrhaging; epidural hematoma, which can permanently paralyze an individual; stroke, and so forth.

In 2012, barely a year after it was made available in the market, the FDA already received about 2081 reports of adverse events linked to Xarelto (151 of these cases were fatal). The most common, and one of the most dangerous effects commonly linked to new generation anticoagulants is excessive internal bleeding. In the case of Warfarin, the anticoagulant approved in 1954, bleeding could be reversed by the consumption of vitamin K. This is not the case for Xarelto and modern blood thinners, though, which do not have reversal agents for the bleeding they cause, making the side-effect irreversible and, so, deadly for many patients.

Xarelto lawsuits are global concerns for Johnson & Johnson and Bayer Health Care. As majority of the four million patients (in the US) have been prescribed with the drug in the past, lawsuits are only predicted to shoot up.

Excessive bleeding, brain hemorrhaging and failure to properly label the drug (to inform users of the drug’s severe effects) are the most common bases of the lawsuits facing the Xarelto’s manufacturers.


read more